Identification of an Immune-Related Risk Signature Correlates With Immunophenotype and Predicts Anti-PD-L1 Efficacy of Urothelial Cancer

Identification of an Immune-Related Risk Signature Correlates With Immunophenotype and Predicts Anti-PD-L1 Efficacy of Urothelial Cancer

Immune checkpoint inhibitor (ICI) treatment has been used to treat advanced urothelial cancer. Molecular markers might improve risk stratification and prediction of ICI benefit for urothelial cancer patients. We analyzed 406 cases of bladder urothelial cancer from The Cancer Genome Atlas (TCGA) data...

Full description

Bibliographic Details
Main Authors: Pengju Li, Shihui Hao, Yongkang Ye, Jinhuan Wei, Yiming Tang, Lei Tan, Zhuangyao Liao, Mingxiao Zhang, Jiaying Li, Chengpeng Gui, Jiefei Xiao, Yong Huang, Xu Chen, Jiazheng Cao, Junhang Luo, Wei Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-03-01
Series:Frontiers in Cell and Developmental Biology
Subjects:
immune-related risk signature
immunity gene
immune checkpoint inhibitor
urothelial cancer
tumor microenvironment
Online Access:https://www.frontiersin.org/articles/10.3389/fcell.2021.646982/full

Internet

https://www.frontiersin.org/articles/10.3389/fcell.2021.646982/full

Similar Items